| Patent application number | Description | Published |
|---|
| 20080293639 | PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES CHARACTERIZED BY AN INFLAMMATORY RESPONSE - This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route. | 11-27-2008 |
| 20090163408 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES - This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues when orally administered in conjunction with a peptide pharmaceutical (e.g., a class A amphipathic helical peptide as described herein) significantly increases the bioavailability of that peptide. Methods of peptide delivery using such “delivery agents” and pharmaceutical formulations are provided. | 06-25-2009 |
| 20090286741 | METHODS FOR IMPROVING THE STRUCTURE AND FUNCTION OF ARTERIOLES - The present invention relates to the unexpected finding that vessels smaller than even the smallest arteries (i.e. arterioles) thicken, become dysfunctional and cause end organ damage to tissues as diverse as the brain and the kidney. This invention provides a method to improve the structure and function of arterioles and preserve the function of end organs such as the brain and kidney. | 11-19-2009 |
| 20100143444 | PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES ASSOCIATED WITH EYE DISEASE - This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection. | 06-10-2010 |
| 20100227825 | PEPTIDES AND PEPTIDE MIMETICS TO TREAT CANCER - This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route. | 09-09-2010 |
| 20100240598 | PEPTIDES AND PEPTIDE MIMETICS TO INHIBIT THE ONSET AND/OR PROGRESSION OF FIBROTIC AND/OR PRE-FIBROTIC PATHOLOGIES - This invention provides methods of inhibiting the onset or progression of a fibrotic disease (or pre-fibrotic pathology) in a mammal. The method involves administering oen or more peptides (e.g., class A amphipathic helical peptides, G* peptides, etc.) as described herein to a mammal in need thereof, in an amount effective to inhibit the onset and/or progression of the fibrotic disease (or pre-fibrotic condition) in the mammal. In certain embodiments the fibrotic disease is selected from the group consisting of retroperitoneal fibrosis (RPF), hepatic fibrosis and/or chirrhosis, renal fibrosis, and pancreatic fibrosis | 09-23-2010 |
| 20110183889 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS - This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues can be reacted with a therapeutically active peptide to produce a modified peptide complex that shows increased resistance to proteolysis and that shows higher bioactivity when orally administered than the unmodified peptide. | 07-28-2011 |
| 20120004720 | G-TYPE PEPTIDES AND OTHER AGENTS TO AMELIORATE ATHEROSCLEROSIS AND OTHER PATHOLOGIES - This invention provides novel peptides, and other agents, that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The peptides are highly stable and readily administered via an oral route. | 01-05-2012 |
